NASDAQ:PRQR

ProQR Therapeutics Stock Forecast, Price & News

$5.41

-0.08 (-1.46 %)

(As of 07/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.31

▼

$5.67

50-Day Range

$5.39

▼

$7.59

52-Week Range

$3.40

▼

$9.46

Volume400,274 shs

Average Volume1.92 million shs

Market Capitalization$271.61 million

P/E RatioN/A

Dividend YieldN/A

Beta0.52

30 days | 90 days | 365 days | Advanced Chart

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Is ProQR Therapeutics (NASDAQ:PRQR) Weighed On By Its Debt Load?
July 19, 2021 | finance.yahoo.com

ProQR Therapeutics N.V. Ordinary Shares (PRQR)
July 18, 2021 | nasdaq.com

ProQR Therapeutics (NASDAQ:PRQR) Short Interest Down 15.3% in June
July 7, 2021 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) and Acerus Pharmaceuticals (OTCMKTS:ASPCF) Critical Contrast
July 5, 2021 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Recommendation of "Buy" from Brokerages
July 3, 2021 | americanbankingnews.com

ProQR to Present at Upcoming JMP Securities Life Sciences Conference
June 10, 2021 | finance.yahoo.com

ProQR Therapeutics(PRQR)
May 23, 2021 | fool.com

What Kind Of Investors Own Most Of ProQR Therapeutics N.V. (NASDAQ:PRQR)?
May 18, 2021 | finance.yahoo.com

ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact
May 4, 2021 | finance.yahoo.com

ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
May 4, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRQR
Previous Symbol
CUSIPN/A
CIK1612940
Webwww.proqr.com
Phone(188) 166-7000
Employees150
Year FoundedN/A

Sales & Book Value

Annual Sales$10.80 million
Price / Sales25.15
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.29 per share
Price / Book4.19

Profitability

EPS (Most Recent Fiscal Year)($1.06)
Net Income$-53,190,000.00
Net MarginsN/A
Return on Equity-68.26%
Return on Assets-43.67%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares50,205,000
Market Cap$271.61 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.66 out of 5 stars

Medical Sector

753rd out of 4,434 stocks

Pharmaceutical Preparations Industry

349th out of 1,734 stocks

3.5 Analyst's Opinion

Consensus Rating
ProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.40, ProQR Therapeutics has a forecasted upside of 461.9% from its current price of $5.41.
Amount of Analyst Coverage
ProQR Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
ProQR Therapeutics has received 288 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ProQR Therapeutics has received 291 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ProQR Therapeutics has received 50.26% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote “Outperform” if you believe PRQR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ProQR Therapeutics does not currently pay a dividend.
Dividend Growth
ProQR Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
86.43% of the stock of ProQR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ProQR Therapeutics are expected to grow in the coming year, from ($1.06) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ProQR Therapeutics is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProQR Therapeutics is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ProQR Therapeutics has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than ProQR Therapeutics?

Wall Street analysts have given ProQR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ProQR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a drop in short interest in June. As of June 15th, there was short interest totaling 1,660,000 shares, a drop of 15.3% from the May 31st total of 1,960,000 shares. Based on an average trading volume of 3,410,000 shares, the short-interest ratio is currently 0.5 days. Approximately 3.1% of the shares of the stock are short sold.
View ProQR Therapeutics' Short Interest.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ProQR Therapeutics.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.01. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $2.40 million.
View ProQR Therapeutics' earnings history.

How has ProQR Therapeutics' stock price been impacted by COVID-19?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRQR shares have decreased by 22.7% and is now trading at $5.41.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for PRQR?

4 brokers have issued 1-year price objectives for ProQR Therapeutics' stock. Their forecasts range from $20.00 to $44.00. On average, they anticipate ProQR Therapeutics' stock price to reach $30.40 in the next year. This suggests a possible upside of 461.9% from the stock's current price.
View analysts' price targets for ProQR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:

Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 38, Pay $834.33k)
Mr. Gerard Platenburg, Co-Founder & Chief Innovation Officer (Age 57)
Ms. Smital Shah M.B.A., Chief Bus. & Financial Officer (Age 45)
Dr. Naveed K. Shams M.D., Ph.D., Chief Scientific Officer (Age 65)
Ms. Sarah Cue Kiely, VP of Investor Relations & Corp. Communications
Ms. Sheila Sponselee, VP of HR
Mr. Bart Klein, Sr. VP of Intellectual Property
Ms. Bianca Matthee, Head of Manufacturing and Pharmaceutics
Mr. Aniz Girach M.D., Chief Medical Officer (Age 54)
Ms. Tiffany Burt, Head of Commercial & VP

Who are some of ProQR Therapeutics' key competitors?

Some companies that are related to ProQR Therapeutics include Dynavax Technologies (DVAX), Nkarta (NKTX), ChemoCentryx (CCXI), CannTrust (CNTTF), CytoDyn (CYDY), Phibro Animal Health (PAHC), Dyne Therapeutics (DYN), Phathom Pharmaceuticals (PHAT), Edgewise Therapeutics (EWTX), Amphastar Pharmaceuticals (AMPH), Kiniksa Pharmaceuticals (KNSA), Humanigen (HGEN), ESSA Pharma (EPIX), Rhythm Pharmaceuticals (RYTM) and Kinnate Biopharma (KNTE).
View all of PRQR's competitors.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $5.41.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $271.61 million and generates $10.80 million in revenue each year. The biopharmaceutical company earns $-53,190,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 150 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

Where are ProQR Therapeutics' headquarters?

ProQR Therapeutics is headquartered at Zernikedreef 9, Leiden P7, 2333 CK.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here